RMACT's IVF with CCS Opportunity Plan is the only all-inclusive IVF treatment plan that includes embryo screening.
When IVF is required for a patient to conceive, RMACT has the ability to screen each and every embryo for chromosomal abnormalities before the embryo is transferred back into the uterus. The purpose of CCS is to identify and transfer only embryos that do not have abnormalities in their number of chromosomes. These chromosomal abnormalities- termed Aneuploidy- refer to the un-balanced number of chromosomes that can be passed down from the egg or sperm. Screening embryos in advance can help achieve higher implantation rates and fewer pregnancy losses. Patients who could benefit from CCS include: women 35 or older, those with multiple-failed IVF cycles and those patients with recurrent miscarriages.
To help make this advanced technology accessible to as many patients as possible, RMA of Connecticut offers our IVF with CCS Opportunity Plan. This unique payment plan is available exclusively to RMACT patients who do not have insurance coverage for their fertility treatments.
RMA of Connecticut no longer offers the IVF with CCS Opportunity Plan, please see the IVF with PGS Opportunity Plan.